The α-adrenoceptor antagonist properties of the enantiomers of doxazosin in the human prostate

European Journal of Pharmacology

Volumn 313, Issue 1-2, 1996, Pages 135-143

  Hatano, Akihiko ^a   Tang, Rui ^a   Walden, Paul D ^a   Lepor, Herbert ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adrenoceptor; cDNA; Doxazosin; Enantiomer; Fibrblast, rat 1; Prostate

Indexed keywords

5 METHYLURAPIDIL; ALPHA 1 ADRENERGIC RECEPTOR; DOXAZOSIN; RECEPTOR SUBTYPE; TERAZOSIN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL MEMBRANE; CONTROLLED STUDY; ENANTIOMER; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MOLECULAR CLONING; MUSCLE TONE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; RAT; TECHNIQUE;

EID: 0030579074     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00502-X     Document Type: Article

References (38)

1. Arunlakshana, O. and H.O. Schild, 1959, Some quantitative uses of drug antagonists, Br. J. Pharmacol. Chemother. 14, 48.
2. Bylund, D.B., D.C. Eikenburg, J.P. Hieble, S.Z. Langer, R.J. Lefkowitz, K.P. Minneman, P.B. Molinoff, R.R. Ruffolo, Jr. and U. Trendelenburg, 1994, IV. International union of pharmacology nomenclature of adrenoceptors, Pharmacol. Rev. 46, 121.
3. Caine, M., 1986, The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy, J. Urol. 136, 1.
4. Caine, M., A. Pfau and S. Perlberg, 1976, The use of alpha-adrenergic blockers in benign prostatic obstruction, Br. J. Urol. 48, 255.
5. Caine, M., S. Raz and M. Zeigler, 1975, Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck, Br. J. Urol. 47, 193.
6. 1-Adrenoceptor classification: sharpening Occam's razor, Trends Pharmacol. Sci. 15, 167.
7. 1c subtype, Mol. Pharmacol. 45, 703.
8. Fulton, B., A.J. Wagstaff and E.M. Sorkin, 1995, Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia, Drugs 49, 295.
9. Graham, R.M. and W.A. Pettinger, 1979, Effects of prazosin and phentolamine on arterial pressure, heart rate, and renin activity: evidence in the conscious rat for the functional significance of the presynaptic α-receptor, J. Cardiovasc. Pharmacol. 1, 497.
10. Gup, D.I., E. Shapiro, M. Baumann and H. Lepor, 1990, Autonomic receptors in human prostate adenomas, J. Urol. 143, 179.
11. 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery, Br. J. Pharmacol. 113, 723.
12. Hedlund, H., K.-E. Andersson and A. Ek, 1983, Effects of prazosin in patients with benign prostatic obstruction, J. Urol. 130, 275.
13. 1adrenoceptors: consensus update, Pharmacol. Rev. 47, 267.
14. Hieble, J.P., M. Caine and E. Zalaznik, 1985, In vitro characterization of the α-adrenoceptors in human prostate, Eur. J. Pharmacol. 107, 111.
15. 1C-adrenergic receptor, Biochem. Biophys. Res. Commun. 195, 902.
16. Honda, K. and C. Nakagawa, 1986, Alpha-1 adrenoceptor antagonist effects of the optical isomers of YM-12617 in rabbit lower urinary tract and prostate, J. Pharmacol. Exp. Ther. 239, 512.
17. 1-adrenoceptor antagonist and its individual optical enantiomers, Naunyn-Schmiedeberg's Arch. Pharmacol. 336, 295.
18. 1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog, Urology 44, 52.
19. Knepper, S.M., S.A. Buckner, M.E. Brune, J.F. DeBernardis, M.D. Meyer and A.A. Hancock, 1995, A-61603, a potent α1-adrenergic receptor agonist, selective for the α1A receptor subtype, J. Pharmacol. Exp. Ther. 274, 97.
20. 1 adrenoceptors using radioligand receptor binding on slide-mounted tissue section, J. Urol. 150, 2002.
21. Kuhar, M.J. and J.R. Unnerstall, 1990, Receptor autoradiography, in: Methods in Neurotransmitter Receptor Analysis, eds. H.I. Yamamura, S.J. Enna and M.J. Kuhar (Raven, New York) p. 177.
22. Kyncl, J.J., B.W. Horrom, C.W. Nordeen, E.N. Juberg and E.N. Bush, 1990, Terazosin enantiomers: alpha adrenoceptor interaction and antihypertensive properties, Eur. J. Pharmacol. 183, 828.
23. Langer, S.Z., I. Cavero and R. Massingham, 1980, Recent developments in noradrenergic neurotransmission and its relevance to the mechanism of action of certain antihypertensive agents, Hypertension 2, 372.
24. 1 adrenergic receptors in human benign prostatic hyperplasia, J. Urol. 132, 1226.
25. Lepor, H., D.I. Gup, M. Baumann and E. Shapiro, 1988a, Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia, Urology 32 (Suppl.), 21.
26. 1-adrenoceptor binding sites in the brain and prostate, Br. J. Pharmacol. 95, 139.
27. Lepor, H., M. Baumann and E. Shapiro, 1988c, The alpha adrenergic binding properties of terazosin in the human prostate adenoma and canine brain, J. Urol. 140, 664.
28. 1-blocker for the treatment of symptomatic benign prostatic hyperplasia, J. Urol. 144, 1393.
29. Lepor, H., M. Baumann and E. Shapiro, 1990b, Binding and functional properties of doxazosin in the human prostate adenoma and canine brain, Prostate 16, 29.
30. 1c-)adrenoceptor subtype, Br. J. Pharmacol. 115, 781.
31. 1-Adrenoceptor properties of terazosin HCl and its enantiomers in the human prostate and canine brain, Prostate 20, 159.
32. 1 adrenergic receptor subtypes in human prostate, J. Urol. 150, 546.
33. 1-adrenergic receptor subtypes in human tissues: implications for human α-adrenergic physiology, Mol. Pharmacol. 45, 171.
34. Saeed, M., O. Sommer, J. Holtz and E. Bassenge, 1982, α-Adrenoceptor blockade by phentolamine causes β-adrenergic vasodilation by increased catecholamine release due to presynaptic α-blockade, J. Cardiovasc. Pharmacol. 4, 44.
35. 3H]rauwolscine, J. Urol. 135, 1038.
36. 2 adrenergic receptors in canine prostate: biochemical and functional correlations, J. Urol. 137, 565.
37. 1C-adrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types, Br. J. Pharmacol. 115, 1475.
38. 1-adrenoceptor antagonist binding in human prostate and aorta, Clin. Exp. Pharmacol. Physiol. 21, 405.